Pegylated liposomal doxorubicin (Doxil, Caelyx) is a formulation of doxorubicin in poly(ethylene glycol)-coated (stealth) liposomes with a prolonged circulation time and unique toxicity profile. 
This report contains market size and forecasts of Pegylated Liposomal Docorubicin in global, including the following market information:
Global Pegylated Liposomal Docorubicin Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Pegylated Liposomal Docorubicin Market Sales, 2017-2022, 2023-2028, (K Units)
Global top five Pegylated Liposomal Docorubicin companies in 2021 (%)
The global Pegylated Liposomal Docorubicin market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
10ml Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Pegylated Liposomal Docorubicin include J&J, Sun Pharmaceutical, CSPC, Kinyond, Teva, Fudan-Zhangjiang, Zydus Cadila and TTY Biopharma, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Pegylated Liposomal Docorubicin manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Pegylated Liposomal Docorubicin Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Pegylated Liposomal Docorubicin Market Segment Percentages, by Type, 2021 (%)
10ml
5ml
25ml
Global Pegylated Liposomal Docorubicin Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Pegylated Liposomal Docorubicin Market Segment Percentages, by Application, 2021 (%)
Breast Cancer
Liver Cancer
Kidney Cancer
Multiple Myeloma
Ovarian Cancer
Other
Global Pegylated Liposomal Docorubicin Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Pegylated Liposomal Docorubicin Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Pegylated Liposomal Docorubicin revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Pegylated Liposomal Docorubicin revenues share in global market, 2021 (%)
Key companies Pegylated Liposomal Docorubicin sales in global market, 2017-2022 (Estimated), (K Units)
Key companies Pegylated Liposomal Docorubicin sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
J&J
Sun Pharmaceutical
CSPC
Kinyond
Teva
Fudan-Zhangjiang
Zydus Cadila
TTY Biopharma